UWA Logo What's On at UWA
   UWA HomeProspective Students  | Current Students  | Staff  | Alumni  | Visitors  | About  |     Search UWA    for      

SEMINAR: Bioporintonomics – Can we in fact print tissue and organs or did we neglect genuinely that biology matters

* Login to add events... *
Today's date is Wednesday, April 21, 2021
Bioporintonomics – Can we in fact print tissue and organs or did we neglect genuinely that biology matters : School of Human Sciences Seminar Series - 3 April, 2018 (Prof. Dietmar Hutmacher) Other events...
Abstract: InAdditive manufacturing (AM) —the industrial version of 3D printing—is a revolutionary method which has tremendous potential in numerous applications areas in science and industry. AM allows rapid design and fabrication of highly customized parts e.g. it has been used to produce prototypes for engineers and designers, 3D printing for consumers and small business entrepreneurs has received a great deal of publicity recently. However, it is in manufacturing where the technology will ultimately have its most significant scientific and commercial impact. Many research challenges remain in translating the early promise of AM to industrial success in design & manufacturing of functional components and systems. Fabrication of high performance components using 3D printing is still a subject of intense research especially for multimaterial and multicomponent products and parts. Additive Biomanufacturing (ABM) is an emerging field within Advanced Manufacturing. ABM has unique technical needs and requirements in the bioprinting community combined with the quest for fundamental and translational research. Bioprinting is a sub-discipline of 3D printing, or the computer aided design and automated fabrication of tissues and organs. Bioprintng uses the principles of computer aided design (CAD) and additive manufacturing to combine scaffolds, cells embedded in hydrogels, also defined as bioinks, into a product that potentially can replace diseased or injured tissue or, as shown more recently in my lab as well as at other world leading biofabrication labs, the development of “in vitro biological constructs” for drug testing and/or personalised medicine concepts. While bioprinting processes have not advanced as greatly as 3D printing in recent years, many more challenges remain to be addressed, such as limited biomaterials available for use in ABM processes, relatively poor dimensional accuracy caused by the stair-stepping effect, insufficient repeatability and consistency of the produced in vitro biological constructs, and lack of in-process qualification and certification methodologies. In order to realize ABM’s potential to usher in the “fourth biomaterial revolution,” the tissue engineered constructs must be fabricated precipitately, economically, and reasonably quickly while meeting stringent functional requirements; such as 1) scaffold’s structural integrity, strength stability, and degradation, as well as cell-specific pore, shape, size, porosity, and inter-architecture; 2) biological requirements regarding cell loading density and spatial distributions, as well as cell attachment, growth, and new tissue formation; 3) mass transport considerations regarding pore topology and inter-connectivity; 4) anatomical requirements regarding anatomical compatibility and geometric fitting. As in the progression of many other emerging technologies, the greatest scientific advancements will come at the boundaries of fundamental material science, physics, engineering, chemistry, and biology. Significant research efforts are essential to expedite the transformation from random bioprinting to additive biomanufacture of innovative biomaterials that claim material flexibility, the ability to generate fine features, and high throughput. The primary take home message from this talk is that the biomaterials community need to go beyond established single material bioprinting processes, and applications that exhibit conventional levels of functionality to move beyond the state of the art and to perform ground-breaking research to underpin multi-material and multifunctional ABM processes and design systems. Such highly innovative multi material & multifunctional ABM platforms will effectively allow the biomanufacturing (defined as first printing of cells in bioinks and then further in vitro and/or in vivo phase) of tissues that are not only optimised to have tissue-specific biochemical and physical properties but, critically, provide maximum biological functional utility to the user in a wide range of applications. It is undoubteldy this shift in perspective, I propose in this talk, that will be the key driving force behind the evolution and innovation of the field of Additive Biomanufacturing in the years to come.
Speaker(s) Prof. Dietmar Hutmacher
Location John Bloomfield Lecture Theatre, UWA School of Human Sciences (Exercise and Sport Science) adjacent to Parkway Entrance 3.
Contact Christine Page <[email protected]>
Start Tue, 03 Apr 2018 13:30
End Tue, 03 Apr 2018 14:30
Submitted by Christine Page <[email protected]>
Last Updated Fri, 11 May 2018 11:05
Included in the following Calendars:
Additional Information:
  • Locations of venues on the Crawley and Nedlands campuses are available via the Campus Maps website.
  • Download this event as: Text | iCalendar
  • Mail this event:

Top of Page
© 2001-2010  The University of Western Australia
Questions? Mail [email protected]